drugset
drugset / Trial / NCT00687609

Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE

NCT00687609 ↗

Phase 4 Terminated 7 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.

Timeline

Start
2008-09
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 1.2 mg/kg Oral

Indications

attention deficit-hyperactivity disorder substance abuse